Contact us  HCVets@gmail.com

Follow us on Facebook

One on One Support

Health Concerns
VA Issues  

 


Information:
Notice: Website under construction,
Contact
HCVets@gmail.com  
 

May 2014 VA Hep C Treatment Guidelines
UPDATE: Feb 26, 2016-
Funding and Prioritization Status Update

UPDATE: March 2016
VA Hep C Treatment Guidelines
VA to treat all vets in system
 

By Judith Graham
VA Extends New Hepatitis C Drugs to All Veterans in Its Health System

 
Orange Count Registry
Vietnam vets blame 'jet guns' for their hepatitis C
By Lily Leung Feb. 14, 2016 
 
CBS News Investigates
Congress outraged over hepatitis C treatment VA can't afford
Dr. Raymond Schinazi played a leading role developing a drug that cures hepatitis C while working seven-eighths of his time for the VA
 
ibtimes.com| By amynordrum
 


Hepatitis C drug costing VA, DoD millions
By Patricia Kime, Staff writer
We're looking at a company who is milking a cash cow for everything it's worth," Sanders said. 
 


VA to outsource care for 180,000 vets with hepatitis C
Dennis Wagner, The Arizona Republic 12:27 a.m. EDT June 21, 2015
 


VA to outsource care for 180,000 vets with hepatitis C
, The Republic | azcentral.com 11:51 a.m. MST June 19, 2015
Dr. David Ross, the VA's director public-health pathogens programs, resigned from the working group. "I cannot in good conscience continue to work on a plan for rationing care to veterans," he wrote.
 


VA Region Stops Referring Patients To Outside Hospitals Thanks To Budget Shortfall
Michael Volpe Contributor ...According to a memo — the entire region has been forced to stop all “non-VA care” referrals due to a budget shortfall.
 

DisabledVeterans.org
OIG INVESTIGATES VA CHOICE PROGRAM PROBLEMS
Sen. Mark Kirk admitted the VA Choice Program is a failed joke in a letter to Secretary Bob McDonald despite attempts to fix it.
 

 
Denied Hep C VA dental care?
Please click here

 
Dried Hepatitis C Blood Exposure 11/23/2013 Weeks later inconspicuous blood transmits virus and more likely to cause accidental exposures to Hep C
 

Lack of Standards for
Mass Vaccinations
1970 Jetgun Nursing Instructions
 

2014 AASLD Study Hepatitis C not an STD

Home
Test the Rest Campaign
Documentation & Surveillance Alerts
Military Hepatitis History  
Understanding The Liver 
VA Flow Sheet for Cirrhosis
VA Defines Risk Factors
 
Hep C & Pro-Prebiotic
Need to know-Grassroots Research
 
Blog Another12Weeks
One Vets' Journey Though Treatment
 

 Ask NOD
 What Would Veterans Do?
Blog for VA Claims
 


Help with VA Claims
 


 
Info: Plan Backfires-
VBA Fast Letter Boost Claims
 
Legal- Fed Regs state:
Judge decision may be relied upon
Cotant v. Principi, 17 Vet.App. 116, 134 (2003),
 
Service Connected Claims
# 1 Conclusion of Law 
# 2 Conclusion of Law 
 
More Claims
Jetgun Decisions
Hep C Decisions

BVA Granted Claims
Nexus Letters
Doctors Testimony

VA physicians
Private Physicians
 
Search Board of Appeals Website
BVA Jetgun Decisions
BVA Hepatitis C Decisions

Great Advice!  
After the jetgun win
What to do next

 

 

2004
Web http://www.google.com/patents/US6802826

" In the past, jet injectors such as Ped-O-Jet®, Ammo-Jet®, and similar mass campaign jet injectors were brought to health care systems. Such injectors had no provision for preventing the transfer of blood-borne pathogens  except through the complicated disassembly and disinfecting process. In mass immunization campaigns these types of injector systems fell out of favor starting in the mid and late 1980's when it was determined that bodily fluids are easily transmitted from one patient to another."

Patents

Publication number US6802826 B1
Publication type Grant
Application number US 09/685,499
Publication date Oct 12, 2004
Filing date Oct 10, 2000
Priority date Oct 11, 1999
Fee status Paid
 
Universal anti-infectious protector for needleless injectors
US 6802826 B1
Abstract
Disclosed is a medical device used to prevent the cross contamination of patients or injectors.
Images(5)
 
Claims(29)
What is claimed is:
1. An injector assembly, comprising:
a) an injector having a proximal end and a distal end, the injector comprising an injector orifice at the distal end;
b) a first component, the first component having an orifice therethrough, the first component generally located at the injector distal end;
c) a second component, the second component having an orifice therethrough, the second component generally located at the injector distal end; and
d) a protective layer generally located at the injector distal end covering at least one of the injector orifice, the first component orifice, or the second component orifice;
wherein the first component, the second component, and the protective layer are configured at the distal end of the injector to block the splashback of debris from entering the injector orifice during and/or after injection.
2. The injector assembly of claim 1, wherein the first component is a baffle.
3. The injector assembly of claim 1, wherein the first component is an insert.
4. The injector assembly of claim 1, wherein the second component is a baffle.
5. The injector assembly of claim 1, wherein the second component is an insert.
6. The injector assembly of claim 1, wherein the first component is proximal to the second component.
7. The injector assembly of claim 1, wherein the protective layer is proximal to either the first component or the second component.
8. The injector assembly of claim 1, wherein the protective layer is proximal to the first and second components.
9. The injector assembly of claim 1, wherein the protective layer is proximal to the second component and distal to the first component.
10. The injector assembly of claim 1, wherein the protective layer covers at least one of the first component orifice and the second component orifice.
11. The injector assembly of claim 1, wherein the injector assembly includes a plurality of protective layers.
12. The injector assembly of claim 11, wherein at least one of the plurality of protective layers is distal to the first or second component.
13. The injector assembly of claim 1, wherein the first component is a baffle, the second component is an insert, and the protective layer is distal to the first component.
14. A medical device, comprising:
a) a first component, the first component having an orifice therethrough;
b) a second component, the second component having an orifice therethrough, the second component being partially distal to the first component;
c) an intermediate piece; and
d) a protective layer, the protective layer located generally between the intermediate piece and the second component orifice.
15. The medical device of claim 14, wherein the intermediate piece further comprises a connector component.
16. The medical device of claim 15, wherein the connector component further comprises at least one of a friction fit, bayonet, and screw type connector.
17. The medical device of claim 16, wherein the intermediate piece further comprises a connector component at each end of the intermediate piece.
18. The medical device of claim 15, wherein the intermediate piece further comprises a connector component at each end of the intermediate piece.
19. The medical device of claim 14, wherein the assembly further comprises an injector.
20. The medical device of claim 19, wherein the injector further comprises a connector component.
21. The medical device of claim 20, wherein the injector connector component is adapted to engage the intermediate piece.
22. The medical device of claim 20, wherein the protective layer is distal to the injector.
23. The medical device of claim 22, wherein the intermediate piece further comprises an orifice extending therethrough.
24. The medical device of claim 23, wherein the intermediate piece orifice is generally coincident with the first and second component orifices.
25. The medical device of claim 24, wherein the protective layer is distal to the injector and proximal to either the first or second component.
26. An injector assembly, comprising:
a) an injector having a proximal end and a distal end, the injector comprising an injector orifice at the distal end;
b) a first component, the first component having an orifice therethrough, the first component generally located at the injector distal end;
c) a second component, the second component having an orifice therethrough, the second component generally located at the injector distal end; and
d) a plurality of protective layers generally located at the injector distal end.
27. The injector assembly of claim 26, wherein at least one of the plurality of protective layers is distal to the first or second component.
28. The injector assembly of claim 26, wherein at least one of the plurality of protective layers is proximal to the first or second component.
29. The injector assembly of claim 26, wherein at least one of the plurality of protective layers is integrally formed with at least one of the first component or the second component.
Description
RELATED APPLICATIONS

This application claims priority from and a benefit to, Russian Patent Application Serial No. 99121141 filed Oct. 12, 1999, now Russian Patent No. 2152227; and Russian Patent Application Serial No. 99124268, filed Nov. 23, 1999, now Russian Patent No. 2152228, in the Federal Institute of Industrial Property of the Russian Federation, the disclosure of which is incorporated by reference herein.

TECHNICAL FIELD OF THE INVENTION

This invention relates to injection devices including, injection devices for intradermal, subcutaneous and intramuscular injections.

BACKGROUND

The most effective measure to prevent many diseases is the mass immunization with vaccines. Since medical science has come to understand the principles of viral theory and its importance to the transmission of diseases, the need to break the viral or bacterial transmission chain from host to host has become well-established. There are wide varieties of methodologies accepted by medical science to break the chain depending on the requirements of the situation. The most stringent protocols include: sterilization, disinfection, and sanitation utilizing heat chemicals and/or ionizing radiation.

Barriers are another common protocol and can be as simple as establishing an imaginary boundary where one side of the boundary is kept clean and the other is defined as contaminated. Any object being transferred from the clean to the contaminated side of the boundary is not returned to the clean side without being disinfected, sanitized, or sterilized. A typical example of this type of protocol is within the medical surgical fields. The surface of the operating table is defined as the boundary. Any item that is dropped below the surface of the operating table is immediately defined as contaminated. This includes surgical implements or the surgeon's hands.

With needle injection devices there are two common protocols both of which start from the premise that a used syringe is, by definition, contaminated. The first, which is commonly used in dentistry, uses syringes and sometimes needles that are sterilized after each use. The second is more commonly used in general medicine in the U.S. and other developed countries. This is the disposable syringe and needle assembly. Because of the low cost of production typically—less than $0.10 per syringe assembly—this protocol is well-accepted.

Jet injector systems on the other hand continue to be characterized by relatively high cost per injection ($1.00 or more) when the syringe portion of the injector is discarded with each use. Additionally, there is the challenge in developing countries where lack of understanding of viral theory and/or a general hoarding mentality discourages following generally accepted protocols within all aspects of health and hygiene. With the identification of blood-borne pathogens like HIV, Hepatitis B, Hepatitis C and others, the need to follow proper protocols becomes more critical.

In the past, jet injectors such as Ped-O-Jet®, Ammo-Jet®, and similar mass campaign jet injectors were brought to health care systems. Such injectors had no provision for preventing the transfer of blood-borne pathogens except through the complicated disassembly and disinfecting process. In mass immunization campaigns these types of injector systems fell out of favor starting in the mid and late 1980's when it was determined that bodily fluids are easily transmitted from one patient to another.

To eliminate the possible transmission of blood-borne pathogens between individuals, disposable or partially disposable jet injector systems were developed. Bio-Jet®, J-Tip®, and others characterize this type of jet injector. General acceptance of these units is limited by relatively high direct costs, even in developed countries like the United States. The standard paradigm of breaking the contamination transmission chain has been addressed by either syringe disposal or designing the syringe so it can easily be decontaminated. Currently, there exists a steadily growing danger of the epidemic diseases (AIDS, hepatitis, tuberculosis and other viral diseases transferred through blood) being transmitted between individuals through the use of needleless injectors.

The traditional needleless injectors comprise the basic design, a housing with an inner power unit, a medication unit, and a nozzle. The function of the power unit pumps the medication into an under-plunger cavity of the medication unit chamber and to expel the medication through the nozzle.

At the initial stage of needleless injector development, when no check valves were used as a control for the functioning of the medication chamber, a method to prevent foreign particles from entering the injector nozzle was to use a sealed nozzle cap. Such cap was limited by the filling of the medication chamber with medication and could not guarantee contamination prevention.

Another approach to the contamination prevention problem has been the use of a disposable, low cost, one-shot nozzle assembly for jet injectors. The nozzle assembly comprises a two-piece molded device incorporating a generally cylindrical nozzle body having a central longitudinal bore of a predefined diameter, extending from a proximal end of the nozzle towards its distal end, terminating in a conical portion of the nozzle. A very small diameter jet-forming bore is formed at the apex of the conical portion of the bore in general. The disadvantage of this device is its lower efficiency (i.e., low vaccination rate) because of poor flow due to the conical design. Moreover, a plastic nozzle element also increases the vaccination cost.

A typical jet injector design has additional drawbacks. Even in the practice of using a protective cap, there is a possibility of infection transfer from one person to another by means of fluids (blood, lymph, medication) reflected from the skin surface during injection (“back splash”) that may get on the nozzle and be transferred from one patient to the next. The protective cap can be a one-shot cap, including the injection nozzle. A purpose of this device is to prevent the multiple use of a cap with a nozzle. This is achieved through the removal, replacement, and/or destruction of the cap at the later stage of the injection. However, cross-contamination continues to be problematic because in the injection stage, the contaminated matter can be transferred through the nozzle to inside the injector such as, for example, into the cavity and be transmitted to a new patient through a new cap and nozzle.

With all the known devices, there is no guarantee that the minimum safety requirements for cross-contamination prevention, as recently introduced (Glenn Austin et al., Gross Contamination Testing of Vaccine Jet Injectors, A Preliminary Report, PATH, Seattle, Wash., 98109), will be achieved. Other studies indicate a very dangerous situation. For example, Russian and Brazilian studies have shown unfavorable data in up to 1.0% of the subjects studied—a level of risk far too great to ignore.

When jet injectors were introduced in the 1940's, they were popular for needle phobic patients or small veined patients. Improvements permitted jet injectors to administer hundreds of millions of vaccinations that saved countless lives. However, when the discovery of pathogen transfer occurred, jet injectors fell out of favour to such an extent that the WHO and the U.S. Department of Defense no longer recommended jet injector.

For example, in the mid-1980's an outbreak of Hepatitis B was caused by use of one high workload injector in a weight loss clinic. See, Canter et al., An Outbreak of Hepatitis B Associated With Jet Injections In A Weight Loss Clinic, Arch. Intern. Med., 150:1923-1927 (1990).

Present parenteral injection technology has recently been deemed by the World Health Organization (WHO) to be incompatible with their requirements for the planned Global Programme of Vaccination and Immunization (GPV) initiatives. It is estimated that 6 additional parenteral vaccines will be recommended for childhood vaccination by the year 2005, requiring a total of 3.6 billion immunization injections per year. The total number of parenteral injections, including injected drugs as well as vaccines, will be roughly ten times this number. This is in addition to the hundreds of millions needed in military induction centers, epidemic situations, worldwide immunizations, and veterinary uses. Major health care providers such as UNICEF, the WHO and CDC have recently confirmed that a radical new technology is required that can be used by personnel with minimal training and that is safer, more convenient, and more comfortable than the syringe and needle. (Jodar L., Aguado T., Lloyd J. and Lambert P-H,(1998) Revolutionizing Immunizations Gen. Eng. News 18, p. 6.)

In other words, what used to be a continent wide life saver, became an undesirable product. The present invention solves problems associated with pathogen transfer and solves many problems associated with the high costs of disposable units.

Accordingly, there is a need in the art of needleless injection devices to solve the problem of cross-contamination during mass vaccinations. More particularly, there is a need for a protector designed for the nozzle head of needleless injectors, which halts “back splash” contamination, and which is low enough in cost to ensure its practical application as a disposable unit even for mass vaccinations.

SUMMARY OF THE INVENTION

The preceding problems are solved and a technical advance is achieved by the present invention. Disclosed is an injector device in which a protective layer in conjunction with other components is used to minimize or eliminate back splash contamination.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1A demonstrates an exploded view of a simple embodiment of the present invention.

FIG. 1B demonstrates the simple embodiment in assembled form.

FIG. 2 shows an exploded view of another embodiment of the present invention in which another component is introduced.

FIG. 3 shows an exploded view of another embodiment of the present invention in which some components are modified.

FIG. 4 shows another embodiment of the present invention in which a protective layer is shown at various positions.

FIG. 5 shows yet another embodiment of the present invention in which an intermediate piece is shown.

FIG. 6 shows yet another embodiment of the present invention in which a protective layer is shown at various positions.

FIGS. 7A-D depict several different embodiments of the protective layer of the present invention.

DETAILED DESCRIPTION

FIG. 1A demonstrates an exploded view of the present invention. An injector assembly 10 is shown. One purpose of the injector assembly 10 is to provide needless injection of medicaments into the skin 12. As described herein, the injector assembly 10 is provided with a layer, such as protective layer 14. The protective layer 14 generally comprises a material that is adapted to permit the injection of medicaments in one direction, yet minimize or retard the reverse flow. In this regard, the protective layer 14 can serve as a back splash guard. In this particular, exemplary, and non-limiting embodiment, an optional baffle 16 is provided to facilitate the diminution of back splash. The source of the medicament jet stream is from the injector 18. Common injectors include Med-E-Jet®, Ped-O-Jet®, Ammo-Jet®, and the like. The baffle 16 further comprises a baffle orifice 20, which can take any desired shape or size, depending on the intended use. In this regard, the size of the baffle orifice 20 will influence how much back splash hits the protective layer 14. It is contemplated in all embodiments that the size of the baffle orifice 20 can be sized to minimize disruption of the medicament jet stream yet maximize the protection afforded by the protective layer 14. If the baffle orifice 20 is too small, the baffle 16 may disrupt the jet stream and thereby reduce the energy of the stream. If too much diminution of the stream energy occurs, then the jet stream will not penetrate the skin 12 in the desired fashion to the desired depth.

Baffle 16 can be sized to accommodate the needed configuration, and may 10 optionally include baffle wings 15. Of course the length and diameters may vary significantly, but in one example, baffle 16 can be approximately greater than 11 mm in diameter and 5 mm tall. Generally, the diameter of the baffle orifice 20 should be slightly larger than the diameter of the jet stream. Therefore, it does not really matter how large the baffle orifice is so long as it is slightly larger than the jet stream diameter, irrespective of the diameter of the injector orifice 22.

Injector 18 has an injector orifice 22 at the distal end of the injector canal 24. The medication sought to be injected travels through the injector canal 24, exits through the injector orifice 22 and punctures the protective layer 14. The medication jet stream then enters the baffle orifice 20 and impacts the skin 12. The energy of the jet stream is chosen to provide the desired injection, depth, and location. For example, for a deeper injection, a higher energy will be necessary. The medicament jet stream then enters the skin 12 and travels to the desired situs. However, the impact on skin 12 is not without some attendant consequences. One consequence is that surface tissue, fluids, cells, and cellular contents are removed or ablated from the surface of skin 12 and fly about. This back splash of debris can travel back along the jet stream and impact the baffle 16 and protective layer 14. The debris, though, is generally not traveling fast enough to re-puncture the protective layer 14. In this regard, the protective layer 14 retards or minimizes the debris back splash into the injector orifice 22 and the injector 18. One function of the layer 14 is to prevent the contamination of the injector. In this regard, the simple concept of the invention is to protect the injector orifice 22 from contamination. Thus, in the event no baffle 16 is used, the injector itself may bear the protective layer 14. Thus, a first component can comprise at least the injector, the baffle, or the insert.

The material chosen for the layer 14 may comprise any material that facilitates a fluid stream puncture in one direction, yet retard the fluid stream puncture in the opposite direction. For example, the layer 14 can comprise a biochemically inert material that is approved for contact with pharmaceuticals, such as but not limited to, at least one of a plastic, rubber, polymer, polyethylene, polytetrafloroethylene, polyurethane, polypropylene, polyolefin, and polysulfone material. In this regard, a material that permits the perforation by the jet stream in one direction but then seals upon itself after the jet stream stops is more desirable. The protective layer or layers are desirably thin, for example greater than 0.001 mm. Preferably and non-exclusively, the thickness can range in the about 0.004 to 0.08 mm range with a further thickness of about 0.2 to 0.5 mm. It should be noted that the thickness chosen is variable. Protective layer 14 may also be textured, woven, braided, or so configured to provide a better adhesion, if necessary, or to provide better attachment, or to prevent or minimize movement. For example, the layer may have grooves of various types. As mentioned, the diameter of the protective layer (if a disc, or the width if a strip) should be slightly larger than the diameter of the jet stream.

As shown in FIG. 1A, the components are in exploded view. In assembly, the baffle 16 can be designed to fit within the injector 18 and sandwich the layer 14 generally between the baffle 16 and injector 18. Desirably, the injector orifice 22 and baffle orifice 16 should line up to minimize any diminution of the stream energy. As with any connection and assembly herein, the baffle 16 can be adapted to provide a friction fit, snap fit, screw fit, or bayonet fit. Any component herein can also be heatsealed to fit. Protective layer 14 can be also adhered, bonded, or otherwise attached to the injector 18, baffle 16 or to any part as desired.

FIG. 1B demonstrates a simple embodiment of the present invention. As one can see, the protective layer 14 can be generally sandwiched between baffle 16 and the injector 18. The protective layer 14 can be totally sandwiched or partially sandwiched between the components described herein. As the medication is injected out through injector canal 24 and injector orifice 22, it will penetrate through the layer 14 and through the baffle orifice 20.

It should be noted that in any embodiment of the present invention, the medication need not be liquid. In addition to aqueous solutions, the present invention may employ suspensions, aqueous gels, emulsions, or controlled release injectable medications. One other dosage form includes powder. For example, Powderject Pharmaceuticals, of Oxford, United Kingdom, and/or Powderject Vaccines (Madison, Wis.) have developed an injector that propels medicine in powder form in the same manner as traditional needleless injectors. For example, see, U.S. Pat. Nos. 5,733,600; 6,053,889; and 5,899,880; the disclosures of which are expressly and entirely incorporated herein. Since the powder form of drugs take up less than 1% of the volume of drugs in liquid form, adapting the powder injectors to be used in accordance with the present invention is also contemplated. Generally, but not exclusively, the powder particles of one dose can range in size but are generally 50 microns wide, as compared to a 500 micron wide syringe needle. In other words, powder form vaccines, such as recombinant DNA based vaccines, including Hepatitis B and HIV vaccines, and other medications for treating influenza, tetanus, erectile dysfunction, allergies, pain, cancer, etc., are contemplated. Such powder forms may be admixed with small amounts of sterile water or other physiologically acceptable diluents (e.g., about 1-10%) to form pastes or suspensions. Therefore, adapting the powder injectors to have a protective cap and/or film consistent with the present invention is within the ordinary skill in the art.

FIG. 2 demonstrates another embodiment of the present invention. The injector assembly 10 is shown having a baffle 16 and an insert 26. The insert 26 can be adapted to form an insert reservoir 27. Insert 26 also has an insert distal orifice 28. Insert 26 can be adapted to fit with baffle 16 such that the insert 26 provides an additional benefit of back splash protection, during or after the injection is completed. Insert 26 can be adapted to fit with baffle 16 such that insert 26 helps to properly tension the skin for the injection type (intramuscular, subcutaneous, or intradermal). As shown in this particular, exemplary, and non-limiting embodiment, the protective layer 14 is generally located between, either partially or completely, the baffle 16 and the injector orifice 22. In this configuration, the jet stream will exit the injector orifice 22, penetrate through the layer 14, and exit through the baffle orifice 20 and insert distal orifice 28 to impact the skin 12. The skin debris will back splash against the insert 26 and any debris that flies into the insert distal orifice 28 will likely be stopped by the baffle 16. In the event that debris trajectory permits debris to travel through the baffle orifice 20, the debris will impact the distal surface 29 of layer 14.

In this regard, the injector orifice 22 is protected against contamination. The debris that hits the protective layer distal surface 29 will likely fall into the insert reservoir 27 and collect there. Insert 26 can be adapted to fit into the baffle 16 as needed. One benefit of the insert configuration is the disposability of the unit. As for configuration, the injector orifice 22 can be some distance away from the skin 12. For example, it can be adjacent the skin 12 (where a baffle or insert is not used and the layer 14 is attached directly to the injector 18), or millimeters away, such as 2-15 mm away. Naturally the distance chosen will reflect on the stream energy. Desirably, the injector orifice 22 distance from the skin 12 is chosen with this in mind. In some configurations, the proximal face of the baffle could be millimeters away from the skin, such as 2-15 mm and desirably 2-7 mm. Insert orifice 28 diameter is also sized accordingly, such as 0.001 mm or greater. In one commercial embodiment, however, the insert 26, baffle 16, and protective layer 14 can be discarded as a unit upon contamination.

FIG. 3 represents another embodiment of the present invention. Shown are the baffle 16, insert 16, protective layer 14, and injector 18. In this configuration the baffle 16 is adapted to provide a greater surface area exposed to potential back splash. The insert 26 is also adapted to minimize back splash contamination. For example, insert 26 has an insert inner surface 30 and an insert outer surface 32. As shown in dotted lines, the insert 26 can be configured to form “wings” in which the insert 26 will cooperate with the baffle 16. Baffle 16 has a baffle inner surface 34 that cooperates with the insert 26. As shown in this embodiment, the insert outer surface 32 is in cooperation with the baffle inner surface 34. The wings of the insert 26 come into proximity of each other to form an insert proximal orifice 36. In this embodiment, any back splash of skin debris entering the insert distal orifice 28 will likely hit the insert inner surface 30, or the baffle inner surface 34, or the distal surface 29 of protective layer 14. In the event insert 26 is configured to not have wings, any debris can still hit the insert inner surface 30, the baffle inner surface 34, or the distal surface 29 of protective layer 14.

FIG. 4 demonstrates yet another embodiment of the invention. Shown is a plurality of protective layers 14 shown in phantom 38. In this exemplary and non-limiting embodiment, the protective layer 14 is shown covering the baffle orifice 20. The protective layer 14 can be integrally formed with the baffle 16 or can be separately affixed to the baffle 16. In this embodiment, the removal of the baffle 16 facilitates disposability. Also shown is that multiple protective layers are present. Protective layers can be generally found proximal the skin, coincident with the insert distal orifice 28, proximal to the insert distal orifice 28, distal to the baffle 16, distal to the baffle orifice 20, coincident with the baffle orifice 20, or proximal to the baffle orifice 20. The number of protective layers can be chosen to maximize the jet stream energy for puncture purposes, but diminish back splash contamination potential. Also shown in FIG. 4 is the assembly in which the insert 26 and baffle 16 are within the injector assembly 18. Where multiple layers are used, the layers can be attached using bonding, heatsealing, or sandwiching the layers.

As seen in FIGS. 7A-D, it should be noted that in any embodiment herein, the protective layer 14 or film need not be a separate piece. Rather it may be integrally formed with a component, such as a septum. For example, the protective layer 14 may be part of the baffle 16 in which that area that will be punctured by the jet stream is adapted to give way during injection. For example, if the baffle 16 is made of plastic, then the area that will serve as the protective layer can be integral with the baffle 16 yet be “ground” down slightly to make it thinner or more easily adapted to perforation. In yet another embodiment, the layer 14 may be separately manufactured then adhered in some fashion to a component, such as the baffle 16. In yet another embodiment as shown in FIG. 7D, a plurality of films may also be used (as shown in phantom lines).

FIG. 5 demonstrates yet another embodiment of the present invention. Baffle 16 is provided with a plurality of baffle legs 40. The baffle legs 40 can be adapted to cooperate with an intermediate piece 42. The intermediate piece 42 has a proximal and distal end such that various components can be attached to either or both ends. In this particular, exemplary, and non-limiting embodiment, intermediate piece 42 has an intermediate piece orifice 44 therethrough. This intermediate piece orifice 44 can be formed by one or more intermediate piece extensions 46. As with any orifice described herein, the size and shape of the orifice may determine the potential back splash contamination and the interruption of the jet stream energy. Intermediate piece 42 can be connected to injector 18 and/or baffle 16 and/or insert 26 via an intermediate piece connector 48. The intermediate piece connector 48 can include any mechanism to attach one piece to another, and can further include a friction fit, bayonet, or screw fitting.

Therefore, as medication is extracted from the medication vial 50, it is drawn into the injector chamber 52 wherein the injection system then delivers the medication through the injector canal 24, through the injector orifice 22, into the intermediate piece 42, through the intermediate piece orifice 44, and then through the various distal components. As shown in FIG. 5, upon exiting the intermediate piece orifice 44, the medication will penetrate the protective layer 14 and then enter the baffle 16 via the baffle orifice 20, then through the insert reservoir 27, through the insert distal orifice 28, to then impact the skin. Skin debris, if it has the correct trajectory, can enter the insert 26-baffle 16 component. Debris can either strike the baffle 16, such as baffle splash guards 54, or insert 26 itself, or can strike the protective layer distal surface 29. In the event that the debris has sufficient energy to re-puncture the layer 14, debris will then strike the intermediate piece 42, such as the intermediate piece extensions 46. In this manner, the only manner in which the injector tip is contaminated is if the debris enters the intermediate piece 42 at such a precise trajectory that is flies through the orifice 44 and directly hits the injector orifice 22. However, although not shown in FIG. 5, a plurality of protective layers 14 can be used at various stages along the insert 26, baffle 26, or intermediate piece 42. Intermediate piece can also include an optional intermediate piece channel 56, which fluidly communicates with the atmosphere and the intermediate piece lumen 57. This permits an equalization of pressure in the lumen 57 and also permits any debris in the lumen 57 to be evacuated. As for size, intermediate piece channel can be approximately any size but may be about 1 mm.

Therefore, the injector assembly 10 provides increased resistance to contamination using a variety of components. It is noted that in any and all embodiments described herein, no individual component is critical or necessary for accomplishing the invention. For example, the embodiment of FIG. 5 can be configured so that it does not have an insert 26, a baffle 16, a protective layer 16, or the intermediate piece 46. In FIG. 5, the addition of the insert 26 and baffle 16 provide added benefit.

FIG. 6 demonstrates yet another embodiment of the present invention. In this embodiment, an insert 26 plays many roles. First, the insert 26 is provided with an insert connector 60, shown here by example only, as a screw fitting. The intermediate piece 42 is provided with an intermediate piece distal connector 62, as shown by example only, as a screw fitting. Accordingly, the intermediate piece distal connector 62 cooperates with the insert connector 60 to provide a detachable attachment. The insert 26 is adapted to provide the same characteristics as the baffle 16 (not shown) in that it can be adapted to also have an insert splash guard 64. While the protective layer 14 is shown proximal to the insert 26, the intermediate piece 42 can also include an intermediate piece protective layer 66 located anywhere along the intermediate piece 42. This intermediate piece protective layer 66 is shown in phantom either distal to the intermediate piece orifice 44, coincident with the orifice 44, or proximal to the orifice 44. In this regard, the intermediate piece protective layer 66 is distal to the injector orifice 22. In operation, the debris that enters the insert 26 will likely impact the insert splash guard(s) 64, the protective layer 14, the intermediate piece extension(s) 46, or the intermediate piece protective layer 66. In this regard, the disposability of the components is enhanced in that the intermediate piece inner surface 68 remains generally clean in that most debris stays within the insert 26 or strikes the protective layers 14, 66.

It is to be understood that although the invention herein described is only illustrative. None of the embodiments shown herein are limiting. It is apparent to those skilled in the art that modifications and adaptations can be made without departing from the scope of the invention as defined by the claims appended.

Patent Citations
Cited Patent Filing date Publication date Applicant Title
US2821891 Dec 1, 1954 Feb 4, 1958 Graflex Inc Diaphragm for photographic cameras
US3057349 Dec 14, 1959 Oct 9, 1962 Aaron Ismach Multi-dose jet injection device
US3292622 Sep 21, 1964 Dec 20, 1966 Banker Oscar H Power operated inoculator
US3461867 Mar 14, 1966 Aug 19, 1969 Mizzy Inc Needleless injector
US3515130 Sep 18, 1967 Jun 2, 1970 Yuryo Kikakuhin Kenkyusho Kk Jet-injection hypodermic device
US3518990 May 2, 1968 Jul 7, 1970 Bay Products Dev Co Gun type inoculator
US3540444 Jan 15, 1968 Nov 17, 1970 Scherer Corp R P Plastic ampoule for use with hypodermic injector
US3788315 Apr 20, 1971 Jan 29, 1974 S Laurens Disposable cutaneous transjector
US3853125 Mar 19, 1973 Dec 10, 1974 W Clark Disposable needleless injector
US4103684 Dec 30, 1976 Aug 1, 1978 Aaron Ismach Hydraulically powered hypodermic injector with adapters for reducing and increasing fluid injection force
US4124024 Mar 3, 1977 Nov 7, 1978 Schwebel Paul R Disposable hypodermic injection ampule
US4165739 Apr 25, 1977 Aug 28, 1979 Doherty Norman R Inoculator
US4266541 Sep 17, 1979 May 12, 1981 Halen-Elliot Do Brazil Industria E Comercio Equipamentos De Precisao Ltda. Pressure hypodermic injector for intermittent vaccination
US4403986 Apr 14, 1982 Sep 13, 1983 Hoechst Aktiengesellschaft Needle-less injection instrument
US4592742 Mar 7, 1985 Jun 3, 1986 Sergio Landau Pressure hypodermic syringe
US4596556 Mar 25, 1985 Jun 24, 1986 Bioject, Inc. Hypodermic injection apparatus
US4722728 Jan 23, 1987 Feb 2, 1988 Patents Unlimited, Ltd. Needleless hypodermic injector
US4850967 Jun 15, 1987 Jul 25, 1989 Sicim Spa Portable endermic injector
US4874367 Feb 5, 1988 Oct 17, 1989 Marpam International, Inc. Hypodermic jet injector and cartridge therefor
US4913699 Mar 14, 1988 Apr 3, 1990 Parsons James S Disposable needleless injection system
US5000737 Jul 26, 1990 Mar 19, 1991 Program For Appropriate Technology In Health (Path) Single use disposable syringe
US5024656 Aug 30, 1988 Jun 18, 1991 Injet Medical Products, Inc. Gas-pressure-regulated needleless injection system
US5049125 May 24, 1988 Sep 17, 1991 Claude Accaries Needleless injection apparatus of a liquid, notably for dental care
US5062830 Apr 4, 1990 Nov 5, 1991 Derata Corporation Dry disposable nozzle assembly for medical jet injector
US5063905 Sep 6, 1990 Nov 12, 1991 Farrell Kenneth R Pneumatic gun
US5085647 Mar 7, 1991 Feb 4, 1992 Sherwood Medical Company Rigid needle cover with needle sealing plug and method of manufacture thereof
US5152751 Dec 4, 1990 Oct 6, 1992 Kozlowski David J Hypodermic needle safety shield
US5171304 Jun 10, 1991 Dec 15, 1992 Duphar International Research B.V. Flexible sealing member for injection device
US5190523 Aug 16, 1991 Mar 2, 1993 Idee International R & D Inc. Disposable syringe and injector
US5222948 Sep 9, 1991 Jun 29, 1993 Path Injection port for single-use syringe
US5256142 Jul 17, 1992 Oct 26, 1993 Sicim Spa Injector administering subcutaneous injections without a needle and with a one-shot cap
US5279608 Dec 4, 1991 Jan 18, 1994 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Osmotic pumps
US5334144 Oct 30, 1992 Aug 2, 1994 Becton, Dickinson And Company Single use disposable needleless injector
US5354286 Dec 7, 1993 Oct 11, 1994 Survival Technology, Inc. Injection device having polyparaxylylene coated container
US5399163 Jul 23, 1993 Mar 21, 1995 Bioject Inc. Needleless hypodermic injection methods and device
US5411492 Jul 5, 1994 May 2, 1995 Sturman; Martin Hypodermic needle protector
US5456388 Sep 21, 1993 Oct 10, 1995 Honstein; Jerry P. Thumbwheel operated metering dispenser for adhesives
US5501666 May 24, 1995 Mar 26, 1996 Mycone Dental Supply Co. Needleless injector
US5503627 May 9, 1994 Apr 2, 1996 Bioject, Inc. Ampule for needleless injection
US5512043 Mar 3, 1994 Apr 30, 1996 Level 1 Technologies Needleless injection site
US5520639 Mar 21, 1995 May 28, 1996 Bioject, Inc. Needleless hypodermic injection methods and device
US5536249 Mar 9, 1994 Jul 16, 1996 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
US5569189 Apr 14, 1995 Oct 29, 1996 Equidyne Systems, Inc. hypodermic jet injector
US5569209 Dec 21, 1994 Oct 29, 1996 Jemm Tran-Safe Systems, Inc. Needleless transfer system
US5573767 Nov 17, 1994 Nov 12, 1996 Societe Anonyme Method for improving the organoleptic qualities of the meat from uncastrated male domestic animals, vaccines which are usable in this method, new peptide, in particular for producing these vaccines and vaccination kit relating thereto
US5584182 Mar 22, 1995 Dec 17, 1996 Abb Management Ag Combustion chamber with premixing burner and jet propellent exhaust gas recirculation
US5593390 Feb 28, 1995 Jan 14, 1997 Visionary Medical Products, Inc. Medication delivery device with a microprocessor and characteristic monitor
US5599302 Jan 9, 1995 Feb 4, 1997 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5618268 Jun 6, 1995 Apr 8, 1997 B. Braun Medical Inc. Medical infusion devices and medicine delivery systems employing the same
US5620434 Jul 10, 1995 Apr 15, 1997 Brony; Seth K. Medicine vial link for needleless syringes
US5643211 Feb 29, 1996 Jul 1, 1997 Medi-Ject Corporation Nozzle assembly having a frangible plunger
US5697917 Feb 29, 1996 Dec 16, 1997 Medi-Ject Corporation Nozzle assembly with adjustable plunger travel gap
US5704911 Dec 8, 1995 Jan 6, 1998 Equidyne Systems, Inc. Needleless hypodermic jet injector
US5713875 Jul 23, 1996 Feb 3, 1998 Abbott Laboratories System for administration of a liquid agent to a patient with a syringe pump
US5716346 Jul 2, 1993 Feb 10, 1998 Farris; Barry Method and apparatus for loading syringes without the need for hypodermic needles
US5722953 Feb 29, 1996 Mar 3, 1998 Medi-Ject Corporation Nozzle assembly for injection device
US5728074 Dec 5, 1994 Mar 17, 1998 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
US5730723 Sep 25, 1996 Mar 24, 1998 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5733600 Nov 13, 1996 Mar 31, 1998 Powderject Vaccines, Inc. Method and apparatus for preparing sample cartridges for a particle acceleration device
US5746714 Jun 7, 1995 May 5, 1998 P.A.T.H. Air powered needleless hypodermic injector
US5746733 Apr 22, 1997 May 5, 1998 Becton, Dickinson And Company Syringe filling and delivery device
US5769138 Apr 1, 1996 Jun 23, 1998 Medi-Ject Corporation Nozzle and adapter for loading medicament into an injector
US5776125 Apr 24, 1995 Jul 7, 1998 Baxter International Inc. Needleless vial access device
US5780100 May 18, 1995 Jul 14, 1998 Powderject Vaccines, Inc. Method and apparatus for preparing sample cartridges for particle acceleration device
US5782802 Jan 30, 1997 Jul 21, 1998 Vitajet Corporation Multiple use needle-less hypodermic injection device for individual users
US5785688 May 7, 1996 Jul 28, 1998 Ceramatec, Inc. Fluid delivery apparatus and method
US5788675 Oct 31, 1995 Aug 4, 1998 Critical Device Corporation Needleless injection site
US5800388 Feb 29, 1996 Sep 1, 1998 Medi-Ject Corporation Plunger/ram assembly adapted for a fluid injector
US5803078 May 26, 1995 Sep 8, 1998 Brauner; Mark E. Methods and apparatus for intrapulmonary therapy and drug administration
US5807374 Aug 14, 1997 Sep 15, 1998 Becton, Dickinson And Company Syringe filling and delivery device
US5814024 Nov 27, 1996 Sep 29, 1998 Elcam Plastics Needleless valve
US5817082 Nov 8, 1996 Oct 6, 1998 Bracco Diagnostics Inc. Medicament container closure with integral spike access means
US5820601 Aug 20, 1996 Oct 13, 1998 Critical Device Corporation Needleless injection site
US5820621 Jul 29, 1997 Oct 13, 1998 Becton, Dickinson And Company Medical fluid transfer and delivery device
US5827244 Aug 23, 1996 Oct 27, 1998 Via Christi Research Inc. Intravenous infusion system
US5830193 Dec 19, 1994 Nov 3, 1998 Higashikawa; Tetsuro Syringe
US5832971 Jul 22, 1996 Nov 10, 1998 Becton, Dickinson And Company Syringe filling and delivery device
US5833213 Aug 7, 1997 Nov 10, 1998 Rymed Technologies, Inc. Multiple dose drug vial adapter for use with a vial having a pierceable septum and a needleless syringe
US5833668 Nov 21, 1996 Nov 10, 1998 Aguilar; David G. Hypodermic syringe
US5833674 Aug 27, 1993 Nov 10, 1998 St. Paul Medical, Inc. Needleless IV medical delivery system
US5836911 Feb 1, 1996 Nov 17, 1998 Medi-Ject Corporation Injection device having positioning means
US5836923 Oct 22, 1996 Nov 17, 1998 Critical Device Corp. Needleless injection site with fixed flow rate
US5839715 Feb 2, 1997 Nov 24, 1998 Alaris Medical Systems, Inc. Medical adapter having needleless valve and sharpened cannula
US5840061 May 14, 1996 Nov 24, 1998 Ferton Holding Ejection apparatus for the high pressure ejection of a liquid
US5840062 Nov 8, 1995 Nov 24, 1998 Gumaste; Anand V. Solid state fluid delivery system
US5846233 Jan 9, 1997 Dec 8, 1998 Medi-Ject Corporation Coupling device for medical injection system
US5851198 Oct 9, 1996 Dec 22, 1998 Visionary Medical Products Corporation Gas pressured needle-less injection device and method
US5858001 Dec 10, 1996 Jan 12, 1999 Elan Medical Technologies Limited Cartridge-based drug delivery device
US5860957 Feb 7, 1997 Jan 19, 1999 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5860961 Mar 13, 1997 Jan 19, 1999 Gettig Technologies, Incorporated Hypodermic injector system and method for maintaining the sterility thereof prior to use
US5860962 Dec 8, 1997 Jan 19, 1999 Becton, Dickinson And Company Shielded cannula for use with an I.V. site
US5865796 Dec 16, 1996 Feb 2, 1999 Powderject Vaccines, Inc Gas driven gene delivery instrument
US5899880 Jun 7, 1995 May 4, 1999 Powderject Research Limited Needleless syringe using supersonic gas flow for particle delivery
US5922685 Jun 5, 1996 Jul 13, 1999 Powderject Vaccines, Inc. IL-12 gene therapy of tumors
US5938637 Mar 14, 1997 Aug 17, 1999 Path Single-use medicine delivery unit for needleless hypodermic injector
US6004286 Sep 18, 1998 Dec 21, 1999 Powderject Research Limited Particle delivery
US6010478 Aug 14, 1997 Jan 4, 2000 Powderject Research Limited Trans-mucosal particle delivery
US6013050 Apr 24, 1997 Jan 11, 2000 Powderject Research Limited Particle delivery
US6053889 Jun 13, 1997 Apr 25, 2000 Powderject Vaccines, Inc. Sample delivery module for particle acceleration apparatus
US6056716 * Oct 25, 1996 May 2, 2000 D'antonio Consultants International Inc. Hypodermic fluid dispenser
US6083197 Oct 1, 1998 Jul 4, 2000 Umbaugh; Jerald C. Spring-actuated needleless injector
US6102896 * Sep 8, 1999 Aug 15, 2000 Cambridge Biostability Limited Disposable injector device
US6224567 * Aug 14, 2000 May 1, 2001 Cambridge Biostability Limited Modified disposable injector device
US6264629 * Feb 18, 1999 Jul 24, 2001 Bioject, Inc. Single-use needle-less hypodermic jet injection apparatus and method
US6270473 * Mar 15, 1996 Aug 7, 2001 Jettek, Inc. Hypodermic jet injector and disposable ampule
US6309371 * Jul 26, 1999 Oct 30, 2001 Medi-Jet Corporation Injection-assisting probe for medical injector assembly
US6383168 * Mar 30, 2000 May 7, 2002 Bioject Medical Technologies Inc. Needleless syringe with prefilled cartridge
US6406456 * Jun 8, 2000 Jun 18, 2002 Avant Drug Delivery Systems, Inc. Jet injector
USD422697 Jan 13, 1999 Apr 11, 2000 Powderject Research Limited Hand held injector
USD428650 Mar 5, 1999 Jul 25, 2000 Powderject Research Limited Injector
EP0526772B1 Jul 13, 1992 Sep 6, 1995 SICIM SpA Injector administering subcutaneous injections without a needle and with a one-shot cap
EP0776224B1 Aug 17, 1995 Dec 9, 1998 PowderJect Research Limited Needleless syringe for particle delivery
EP0788386B1 Oct 20, 1995 Jan 13, 1999 PowderJect Research Limited Needleless syringe
EP0799064B1 Dec 21, 1995 Aug 25, 1999 PowderJect Research Limited Particle delivery
EP0834330B1 Jul 27, 1994 Nov 26, 2003 Aradigm Corporation Needle-less injector
EP0888790A1 Jul 4, 1997 Jan 7, 1999 PowderJect Research Limited Drug particle delivery device
EP0888791A1 Jul 4, 1997 Jan 7, 1999 PowderJect Research Limited Syringe and drug capsule therefor
EP0951917A2 Apr 8, 1994 Oct 27, 1999 PowderJect Research Limited Particle delivery of particularly a powdered therapeutical agent
EP0951917A3 Apr 8, 1994 Jan 5, 2000 PowderJect Research Limited Particle delivery of particularly a powdered therapeutical agent
FR2629348A2       Title not available
FR2641190B3       Title not available
RU2008932C1       Title not available
RU2108117C1       Title not available
WO1997034652A1 Mar 17, 1997 Sep 25, 1997 Bellhouse Brian John Needleless syringe with therapeutic agent particles entrained in supersonic gas flow
WO1997048485A1 Jun 17, 1997 Dec 24, 1997 Burkoth Terry Lee Method for providing dense particle compositions for use in transdermal particle delivery
WO1998013470A1 Sep 25, 1997 Apr 2, 1998 Powderject Vaccines Inc Gas-driven particle delivery device
WO1999001168A1 Jul 3, 1998 Jan 14, 1999 Powderject Res Ltd Drug particle delivery
WO1999001169A1 Jul 6, 1998 Jan 14, 1999 Brian John Bellhouse Syringe and capsule therefor
WO1999008689A1 Aug 21, 1998 Feb 25, 1999 Powderject Vaccines Inc Mucosal immunization using particle-mediated delivery techniques
WO1999027961A1 Dec 2, 1998 Jun 10, 1999 Powderject Vaccines Inc Transdermal delivery of particulate vaccine compositions
WO2000013573A1 Sep 3, 1999 Mar 16, 2000 Kwon Sung Yun Monitoring methods using particle delivery methods
WO2000014547A1 Sep 3, 1999 Mar 16, 2000 Powderject Res Ltd Immunodiagnostics using particle delivery methods
WO2000019982A1 Oct 1, 1999 Apr 13, 2000 Powderject Res Ltd Spray coated microparticles for use in needleless syringes
WO2000023592A2 Oct 19, 1999 Apr 27, 2000 Powderject Vaccines Inc Minimal promoters and uses thereof
WO2000023592A3 Oct 19, 1999 Jul 27, 2000 Powderject Vaccines Inc Minimal promoters and uses thereof
WO2000026385A1 Nov 5, 1999 May 11, 2000 Powderject Vaccines Inc Nucleic acid constructs for genetic immunization
Non-Patent Citations
Reference
1   Dimache, et al., A Clinical Epidemiological and Laboratory Study on Avoiding the Risk of Transmitting Viral Hepatitis During Vaccinations with the Dermojet Protected by an Anticontaminant Disposable Device, Vaccine, vol. 15, No. 8, pp. 1010-1013 (1997).
2   Jet Gun Injection Transmission: A Clinical Epidemiological and Laboratory Study on Avoiding the Risk of Transmitting Viral Hepatitis During Vaccinations with the Dermojet Protected by an Anticontaminant Disposable Device, American Journal of Infection Control, vol. 26, No. 4, pp. 442-445 (Aug. 1998).
Referenced by
Citing Patent Filing date Publication date Applicant Title
US7074210 * Oct 11, 2002 Jul 11, 2006 Felton International, Inc. Universal protector cap with auto-disable features for needle-free injectors
US7156823 * Jun 9, 2003 Jan 2, 2007 Bioject Inc. High workload needle-free injection system
US7789734 Jun 27, 2008 Sep 7, 2010 Xerox Corporation Multi-orifice fluid jet to enable efficient, high precision micromachining
US8540665 Nov 4, 2009 Sep 24, 2013 Powder Pharmaceuticals Inc. Particle cassettes and processes therefor
US8945045 * Jul 20, 2010 Feb 3, 2015 Ams Research Corporation Needleless injection device components, systems, and methods
US9044546 Aug 22, 2013 Jun 2, 2015 Powder Pharmaceuticals Incorporated Particle cassettes and processes therefor
US20040111054 * Jun 9, 2003 Jun 10, 2004 Sergio Landau High workload needle-free injection system
US20060106333 * Apr 18, 2005 May 18, 2006 Leon Nanthaniel J Universal protector cap with auto-disable features for needle-free injectors
US20120109049 * Jul 20, 2010 May 3, 2012 Lund Jonathan J Needleless injection device components, systems, and methods
USRE43824 Jan 11, 2002 Nov 20, 2012 Powder Pharmaceuticals Inc. Needleless syringe
Classifications
   
U.S. Classification 604/192, 604/71, 604/70, 604/268, 604/69, 604/72, 604/68
International Classification A61M5/315, A61M5/30, A61M5/178, A61M5/31, A61M5/20
Cooperative Classification Y10S128/919, A61M5/204, A61M2005/2013, A61M5/30, A61M5/31501, A61M5/178, A61M2005/3104, A61M2005/3118, A61M5/20, A61M5/3134
European Classification A61M5/20, A61M5/178, A61M5/30
Legal Events
Date Code Event Description
Jan 22, 2001 AS Assignment
Owner name: NEEDLELESS VENTURES, INC., KANSAS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FELTON, ALAN;LEON, NATHANIEL;REEL/FRAME:011463/0058;SIGNING DATES FROM 20010110 TO 20010111
Dec 18, 2002 AS Assignment  
Nov 23, 2005 AS Assignment
Owner name: OWENS-ILLINOIS HEALTHCARE PACKAGING, INC., OHIO
Free format text: SECURITY AGREEMENT;ASSIGNOR:FELTON INTERNATIONAL, INC.;REEL/FRAME:016800/0809
Effective date: 20051123
Oct 29, 2007 AS Assignment
Owner name: PULSE NEEDLEFREE SYSTEMS, INC., KANSAS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FELTON INTERNATIONAL, INC.;REEL/FRAME:020031/0266
Effective date: 20071029
Apr 14, 2008 FPAY Fee payment
Year of fee payment: 4
Apr 21, 2008 REMI Maintenance fee reminder mailed  
Jul 12, 2010 AS Assignment
Owner name: FELTON INTERNATIONAL, INC. N/K/A PULSE NEEDLEFREE
Free format text: UCC FINANCING STATEMENT TERMINATION;ASSIGNOR:OWENS-ILLINOIS HEALTHCARE PACKAGING INC.;REEL/FRAME:024662/0561
Effective date: 20100709
Apr 11, 2012 FPAY Fee payment
Year of fee payment: 8